Navigation Links
Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
Date:2/9/2009

SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management's presentation at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 9:30 AM Eastern will be webcast live with slides at http://www.celltherapeutics.com.

The presentation will take place in the Jade Room at the Waldorf-Astoria Hotel, and will also be available for replay after the presentation.

                        BIO CEO & Investor Conference
                 CTI Presentation: Tuesday, February 10, 2009
           9:30 AM Eastern/3:30 PM Central European/6:30 AM Pacific
                       Jade Room, Waldorf-Astoria Hotel
         Audio webcast with slides athttp://www.celltherapeutics.com

     Media Contact:
     Cell Therapeutics, Inc.
     Dan Eramian
     T: 206.272.4343
     F: 206.272.4434
     E: media@ctiseattle.com
    http://www.celltherapeutics.com/press_room

     Investors Contact:
     Cell Therapeutics, Inc.
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch Logan
     T: 206.272.4347
     F: 206.272.4434
     E: invest@ctiseattle.com
    http://www.celltherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
2. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
3. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
7. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
8. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):